Amgen

Open: 226.02 Close: 225.02 Change: -1.0

You'll be sorry if you don't use an AI to decide whether to invest in Amgen.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, block, Horizon, say, deal, Federal, and the most common words in the summary are: amgen, stock, horizon, ftc, news, market, therapeutic, . One of the sentences in the summary was: FTC says deal would enable Amgen to exploit its size to block competition for …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

FTC says deal would enable Amgen to exploit its size to block competition for two expensive Horizon drugs. FTC says it opposed the deal because it was concerned that Amgen could use rebates to pharmacy benefit managers in exchange for promoting Horizons two key products. Amgen said it was disappointed in the decision.

Today's News

Federal Trade Commission sues to block Amgen s $27.8 billion acquisition of Horizon Therapeutics. FTC says the deal would stifle competition in pharmaceutical industry. Federal Trade Commission sues to block Amgen $27.8 billion takeover of Horizon Therapeutics. FTC says deal would enable Amgen to exploit its size to block competition for two expensive Horizon drugs. FTC said it opposed the deal because it was concerned that Amgen could use rebates to pharmacy benefit managers in exchange for promoting Horizons two key products. Amgen has said that neither it nor Horizon plan to bundle. Federal Trade Commission sues to block biopharmaceutical giant Amgen from acquisition that would entrench monopoly drugs used to treat thyroid eye disease and chronic refractory gout treatments. FTC filed a lawsuit in federal court to block the transaction, saying it would enable Amgen to use rebates on its existing blockbuster drugs. Federal Trade Commission filed a lawsuit Tuesday to block Amgens proposed $26 billion acquisition of Horizon Therapeutics by biotech drug developer Amgen on antitrust grounds. FTC said the deal would give Amgen unfair leverage. Federal Trade Commission sues over Amgens $28-billion Horizon Therapeutics deal. FTC says the deal would allow Amgen to entrench its monopoly on medications for thyroid eye disease and chronic refractory gout. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. Amgen revenue was $26.32 billion, an increase of 1.32% compared to the previous years $25.98 billion. Analyst Consensus: Hold Stock Forecasts (11.71% upside) Federal Trade Commission sues to block Amgen acquisition of Horizon Therapeutics. FTC is preparing to seek an injunction in federal court that would prevent the deal from closing. Federal Trade Commission filed a lawsuit on Tuesday seeking to block Amgen Inc.’s proposed $27.8 billion acquisition of Horizon Therapeutics Plc. The FTC is reportedly gearing up to block the deal. Amgen drops drug delivery partnership, targets Crohns Disease with TScan Therapeutics. $27.8 billion deal to acquire Horizon Therapeutic has been blocked by FTC. Federal Trade Commission (FTC) said Tuesday it will sue to stop Amgens $27.8 billion acquisition of Horizon Therapeutics. FTC said in the complaint that Amgen would be able to leverage its position with insurance companies and pharmacy benefit managers wanting access to its blockbuster drugs, while pressuring them into favorable terms. Federal Trade Commission says deal would give Amgen unfair leverage to block competition for Horizon medications. FTC: Deal would allow Amgen to use rebates on existing drugs to pressure bill payers into favoring Tepezz and Krystexxa. Amgen said it was disappointed in the decision but remains committed to completing the deal by December.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, block, Horizon, say, deal, Federal, and the most common words in the summary are: amgen, stock, horizon, ftc, news, market, therapeutic, . One of the sentences in the summary was: FTC says deal would enable Amgen to exploit its size to block competition for two expensive Horizon drugs. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #horizon #ftc #news #market #therapeutic.